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Abstract 
 
Purpose The purpose of this study is to analyze the incidence rate of side effects occurring 
during systemic therapy (corticosteroids, methotrexate, azathioprine, cyclosporine A or 
biologic agents) of auto-immune uveitis.  
 
Material and methods Retrospective study including 23 / 71 patients aged between 0-16 
years old presenting with a chronic non-infectious uveitis. All children were treated in the 
Jules-Gonin Eye Hospital and paediatric rheumatology unit of the CHUV (Centre Hospitalier 
Universitaire Vaudois) between January 2000 and December 31st 2010. Side effects were 
reported as minor (without subsequent change in systemic medication), moderate (associated 
with a change in systemic dosage or class of immunosuppressive therapy or in the presence of 
Cushingoid face or weight gain) or severe (hospitalization or life threatening). 
 
Results 52% of boys and 48% of girls are present in the cohort with a mean age at the first 
visit of 8.1 years (1.7–15.6).  Intermediate uveitis consisted of the commonest aetiology with 
8 patients (35%), juvenile idiopathic arthritis (JIA) in 7 (30%), Behçet’s disease in 3 (13%) 
and others in 5 (22%). The overall length of therapy was longer for prednisone (26.6 ± 5.4 
patient / year), but was similar between methotrexate (22.1 ± 5.4   patient / year) and 
azathioprine (15.2 patient / year). Moderate side effects were respectively 64% for 
corticosteroids therapy, 54% with methotrexate and 14% with azathioprine. One severe and 
one moderate side effect were observed with anti-TNFα respectively stage III anaphylactic 
shock and pain during injection associated with a redness of the site of injection and limping 
after the injection. 
 
Discussion Immunomodulating agents allow a rapid decrease in corticosteroid therapy, but 
one severe side effect was observed with anti-TNFa agents. These agents are considered in 
most countries as third line therapeutic agents. 
 
Key words Uveitis, pediatric, adverse events, corticosteroids, immunosuppressive agents 
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Retrospective analysis of complications of systemic immunosuppressive 
therapies (steroids and immunosuppressive therapies) in pediatric uveitis 
 
Sébastien Fracheboud, Michaël Hofer, Jean D. Vaudaux, Lydia Clarke, 
Yan Guex-Crosier. 
 
Introduction 
 
Uveitis is defined as of inflammation of intraocular structures, such as the ciliary body, the 
choroid and the retina. In most cases, uveitis presents with breakdown of the blood-aqueous 
barrier, resulting in the presence of proteins and cells in the anterior chamber of the eye (SUN 
classification). 
1
 About 6 to 10% of all cases of uveitis occur in children. Uveitis presenting at 
birth or soon after birth are primarily related to congenital infections, while uveitis associated 
with auto-immune diseases occurs more frequently in young children. 
2
 The most common 
systemic associations are juvenile idiopathic arthritis (JIA), sarcoidosis and Behçet’s disease. 
Uveitis in children remains a diagnostic and therapeutic challenge. Early diagnosis is 
mandatory to avoid severe ocular or systemic complications that may occur in the absence of 
adequate therapy. For instance, approximately 50% of eyes with JIA-associated uveitis will 
develop legal blindness in the absence of adequate therapy. 
3
 Therapy must be administered 
systemically, since topical corticosteroids are of limited efficacy on the posterior segment of 
the eye. 
4
 
 
Systemic corticosteroids have been the mainstay of therapy for uveitis affecting the posterior 
segment of the eye (posterior uveitis). Intravenous pulse administration of 
methylprednisolone during three consecutive days followed by oral prednisone has been 
widely used in sight-threatening uveitis. 
5
 However, systemic corticosteroid administration is 
associated with numerous systemic side effects, including growth retardation, Cushing’s 
disease, bone calcium depletion, high blood pressure, salt retention, diabetes, and mood 
swings, or depression. 
6
 Long-standing topical corticosteroids also have the potential for side 
effects that affect the eye, such as cataracts, and ocular hypertension 
7-9
; conversely, ocular 
hypertension may preclude further use of corticosteroids. 
9
 
Recently, guidelines for the therapy of severe uveitis were published, primarily with regard to 
adult uveitis. 
9
 The introduction of corticosteroid-sparing immunosuppressive agents is 
recommended if intraocular inflammation is not under control after one month of high dose 
corticosteroids (prednisone 1 mg/kg/day), if intraocular inflammation is not controlled with a 
 4 
daily-dose of prednisone ≤ 10mg  , in case  of corticosteroid-side effects that require tapering 
or discontinuation of corticosteroids, or in the presence of an ocular inflammatory disease 
known to have poor prognosis with corticosteroids alone. 
6;10
 Regarding childhood uveitis, 
however, very few data are available with respect to the use of, the efficacy, and the potential 
side effects of systemic immunosuppressive therapy. Anti-TNFα agents are a new class of 
immunomodulating drugs that are widely used in the treatment of Behçet’s disease, 
rheumatoid arthritis, JIA, spondylathropathies, Crohn’s disease and psoriasis. 11  These agents 
may be combined to other immunosuppressive therapies to optimize therapeutic efficacy, as it 
was demonstrated in rheumatoid arthritis. 
11
 
 
The purpose of the current study was to analyze the side effects of three different categories 
of therapy (corticosteroids, immunosuppressive drugs and anti-TNFα agents) currently used 
in the management of intraocular inflammation in children.  
 
 
 
Material and methods 
 
Study population 
 
All children presenting with non-infectious uveitis seen in the Uveitis unit of the Jules-Gonin 
Eye Hospital and the Unit of Paediatric Rheumatology of the CHUV (Centre Hospitalier 
Universitaire Vaudois) between January 2000 and December 31
st
 2010 were included in the 
study. Data analysis was primarily focused on patients treated with one of the 3 categories of 
therapy (systemic corticosteroid, antimetabolite agents, and biological agents). 
The Jules-Gonin Eye Hospital and the CHUV have a general authorization that was delivered 
for retrospective analysis of the data. The protocol was conducted in accordance with the 
principles of the Declaration of Helsinki. 
 
Data collection 
Patients were identified from a computerized database of uveitis patients followed at the 
Jules-Gonin Eye Hospital and in the CHUV. Data were collected via retrospective chart 
review and entered into a computerized database, and included demographics, clinical 
features of inflammatory eye disease, and diagnosis. Potential associated systemic diseases 
were thoroughly documented by systemic work-up that was performed in the Paediatrics 
Department as needed and during follow-up when systemic side effects occurred.  Adverse 
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events were classified into three categories: minor (without subsequent change in systemic 
medication); moderate (associated with a change in systemic dosage or class of 
immunosuppressive therapy). In the presence of corticosteroids introduction of 
immunosuppressive therapy as corticosteroid-sparing agents, the presence of a Cushingoid 
face or weight gain was also considered as medium side effects; and severe (associated with 
hospitalization or life-threatening side effects). Side effects of therapy were analyzed 
according to clinical reports that were sent after each clinical visit to the child’s paediatrician 
and according to laboratory work-up. Side effects that occurred most frequently were 
analyzed and documented. The average time interval between initiation of therapy and onset 
of side effects was also recorded for each of the 3 categories of therapy. 
 
 
Statistical analysis 
All statistical analyses were performed using the JMP software. Frequencies of demographic 
and clinical variables were calculated for each variable. Time of follow-up (reported as 
patient / year) was compared according with the Mann-Whithney rank sum test and incidence 
rate of complications were compared. 
 
RESULTS 
 
Seventy-one children with uveitis aged 0 to 16 years were identified in the chart review. All 
these patients were followed-up in the Uveitis Clinic of the Jules-Gonin Eye Hospital in 
Lausanne between January 2000 and December 2010. Of these 71 patients, 23 patients with 
uveitis and systemic therapy were included in the analysis. Demographics and diagnoses are 
summarized in table 1. There were 12 boys and 11 girls. Mean age at presentation was 8.1 
years [range 1.7 to 15.6 years]. Localization of uveitis was unilateral in 4 patients and 
bilateral in 19 patients. Anatomical classification of uveitis was the following: anterior uveitis 
52%, intermediate uveitis 35%, posterior uveitis 4% and panuveitis 9%. Intermediate uveitis 
consisted of the commonest aetiology with 8 patients (35%), juvenile idiopathic arthritis (JIA) 
in 7 (30%) and Behçet’s disease in 3 (13%); distribution is detailed in table 1. All included 
patients were diagnosed with chronic uveitis (of more than 3 months’ duration according to 
the SUN classification) 
1
 that was associated in some cases with rheumatologic disease. 
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The overall length of therapy was longer for prednisone (26.6 ± 5.4 patient / year), but was 
similar between methotrexate (22.1 ± 5.4   patient / year) and azathioprine (15.2 patient / 
year). These two agents are introduced usually as second line therapy. No difference in 
therapeutic time (in term of patient / year) was observed ANOVA p ≤ 0.2346. Moderate and 
severe side effects were respectively 64% for corticosteroids therapy, 54% with methotrexate, 
25% with anti-TNFα and 14% with azathioprine. 
Prednisone therapy was used as first line therapy in 22 out of 23 patients (96%). Control of 
intraocular inflammation could be obtained in 5 patients (23%), allowing progressive tapering 
of the therapy. Whenever intraocular inflammation was not brought under control or in cases 
of long-standing corticosteroid therapy, a corticosteroid-sparing, immunosuppressive agent 
was used as a second line therapy. Among those agents, methotrexate was the most 
commonly used (13 patients, 57% of total) (Figure 1). A control of ocular inflammation could 
be achieved in 7 out of 13 patients. Azathioprine was used in 7 patients (30%), achieving 
control of intraocular inflammation in 4 patients, one patient was previously treated with 
methotrexate. Anti-TNFα agents were used as a third line therapy and whenever control of 
intraocular inflammation was not achieved using either systemic corticosteroid therapy or 
corticosteroid-sparing immunosuppressive drugs. Quiescence of uveitis was obtained in 20/23 
patients minimal inflammation was still present in three patients see figure 1. 
 
In our cohort of patients, minor metabolic side effects were observed in more than 95% of 
patients during the first weeks of therapy (our first line therapy consisted of prednisone 
1mg/kg/day). On 22 patients who received a treatment of prednisone in the cohort 14/22 
(64%) developed one or more moderate secondary effect. Among these moderate secondary 
effects, 9/22 (41%) cases of weight gain have been identified, 6/22 (27%) patients presented a 
change of the percentile of the weight and 5/22 (23%) patients developed a cuschingoïd 
facies. Among the other moderate secondary effects with prednisone, 4/22 (18%) patients 
developed an ocular hypertension, 3/22 (14%) had a lymphopenia, 3/22 (14%) developed a 
cataract, 1/22 (4.5%) developed a glaucoma, 1/22 patient presented an arterial hypertension 
and 1/22 patient presented a delay in the growth and the weight gain with a percentile under 
three. More than one side effect can be observed in the same patient. One patient stopped 
prednisone therapy one day after initiation of therapy in the presence of severe nausea and 
vomiting. The parents refused further use of corticosteroids. This event was reported in the 
moderate side effects in an intention to treat basis. No severe side effects were observed. Long 
term side effects were not reported in this study. 
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With regard to antimetabolites (methotrexate and azathioprine), the most frequently observed 
side effects was elevation of liver function tests SGPT and SGOT. Rarely, lymphopenia was 
documented. Regarding to the secondary effects of the immunomodulating therapies, there 
are more moderate side effects than with prednisone. 13 patients were treated with 
methotrexate and 9/13 (69%) patients developed some secondary effects. 2/9 (22%) patients 
developed a minor secondary effect, 4/9 (44%) patients developed a moderate secondary 
effect, 1/9 (11%) patient presented 2 moderate secondary effects and 2/9 (22%) patients 
developed a minor and a moderate secondary effect. 
Concerning the minor secondary effect, there are 3 cases of lymphopenia and 1 case of liver 
toxicity. The moderate secondary effects are the following: 7 cases of liver toxicity with an 
elevation of the liver enzymes (ASAT/ALAT) and 1 case of severe lymphopenia. 
7 patients were treated with azathioprine: among these patients, 4/7 (57%) patients developed 
a secondary effect. 1/4 (25%) patient presented a minor and a moderate secondary effect and 
3/4 (75%) patients developed a minor secondary effect. The only 1/4 (25%) moderate 
secondary effect was a liver toxicity with an elevation of ASAT. There were 2 cases of liver 
toxicity which didn’t require a change or a stop of the treatment, 1 case of thrombopenia 
associated with a leucopenia and 1 case which concern a decrease of the three bloodlines. 
In the cohort of 23 patients, 1 patient was treated by cyclosporine and presented 1 minor 
secondary effect such as a thrombopenia. 
Regarding the last possible line of treatment, 8 patients were treated by biological agents like 
anti-TNFα and 3/8 (37.5%) patients developed one or two secondary effects. There are few 
secondary effects with these agents. With anti-TNFα agents, only few side effects were 
observed, including slight pain upon injection or elevated liver function tests: 
1/3 (33%) patient presented 2 minor secondary effects with two different molecules: 
etanercept (Enbrel®) and adalimumab (Humira®). 1/3 (33%) patient developed a moderate 
secondary effect and 1/3 (33%) developed a severe secondary effect. The 2 minor secondary 
effects were 1 pain during injection with adalimumab (Humira®), and 1 discrete liver toxicity 
with etanercept (Enbrel®). The moderate secondary effect was a pain during injection 
associated with a redness of the site of injection and limping after the injection concerning 
adalimumab (Humira®). Regarding the severe secondary effect it is an anaphylactic shock 
with an injection of infliximab (Remicade®). Side effects are summarized in table 2 and sides 
expressed as patient / year. Moderate side effects occurred in 14/22 patients with 
corticosteroids (64%). Antimetabolite-related liver toxicity was observed in 7/13 patients 
treated with systemic methotrexate (54%) (Subgroup analysis of oral or IM MTX) and 
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occurred after a mean time of 15.6 months, and in 1/7 patients treated with azathioprine 
(14%) after 6.3 months. Anti-TNFα therapy was associated with stage III anaphylactic shock 
in one patient after infliximab (Remicade®) infusion, and limp, pain and erythema in one 
other patient. 
 
 
DISCUSSION 
 
Approximately 32% of patients (23 out of 71 patients) in the studied group were treated with 
systemic therapy. Therapeutic approach included a stepwise approach consisting of 
corticosteroids as a first line therapy, antimetabolites methotrexate and azathioprine as a 
second line therapy, and eventually anti-TNFα whenever intraocular inflammation was not 
brought under control using the first two lines of therapy or if severe side effects were 
observed. Median time of therapy was longer for corticosteroids than for immunosuppressive 
or biological therapies. With anti-TNFα agents, only few side effects were observed, 
including slight pain upon injection or elevated liver function tests. 
Stage III anaphylactic shock was the most severe side effect observed in one patient of this 
series and occurred with anti-TNFα perfusion (infliximab (Remicade®).  This side effect 
result from idiosynchrasic reaction occurring after proteins perfusion. Infliximab 
(Remicade®) is a chimeric monoclonal antibody and anaphylactic adverse event requires 
cancellation of therapy, cardiopulmonary arrest was recently described in a 37-year-old man 
with no history of allergy or coronary heart disease. 
12
 Perfusion of infliximab (Remicade®) is 
mandatory in inpatient clinic, in the presence of unpredictable anaphylactic reaction (daycare 
hospitalization).  
Most side effects were moderate and related to hepatotoxicity of immunosuppressive drugs, 
all cases were reversible after dosis change of switching to other therapies. A close follow-up 
of complete blood count, urea, creatinine and liver function tests values is mandatory during 
the follow-up of immunosuppressive therapy since this side effect was respectively observed 
in 54% of patients under MTX and 14% of patients under azathioprine.  Infliximab 
(Remicade®) is associated with a better answer of the inflammation than etanercept 
(Enbrel®). 
13
 Infliximab (Remicade®) is better and generate less secondary effects than 
etanercept (Enbrel®). Etanercept (Enbrel®) is more frequently associated with ocular 
complications such as glaucoma or cataract. 
14
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No significant difference was observed between the lengths of follow-up of the different 
group of patients. Corticosteroids were associated with a high rate of minor (more than 95%) 
and moderate metabolic complications. Multiples sides’ effects were also observed in the 
same patients, high dosage of corticosteroids being more susceptible to produce severe sides’ 
effects. This study was not designed to analyzed long term side effects such as osteoporosis or 
bone fractures which are classically described by corticosteroids use. In all patients 
corticosteroids could be stopped after initiation of immunosuppressive therapy or biological 
agents. This approach allows minimizing onset of cataract or corticosteroids-induced 
glaucoma. In this series less than 14% of patients developed a cataract and only one patient 
developed a glaucoma (4.5%). In a mean follow-up of 3.8 years, 27 out of 53 patients (51%) 
with JIA underwent cataract extraction in the series described by Sijssens et al, but JIA 
patients presents probably a higher risk of development of cataract. 
8
 Uveitis-induced 
glaucoma is observed in up to 20% of patients with a 5-years follow-up of uveitis and in more 
than 38% of patients with JIA. 
7
 The relative low rate of ocular complication of our series is 
probably related to the prompt introduction of immunomodulating agents allowing a rapid 
decrease in corticosteroids dosage and limiting topical administration of corticosteroids.   
Anti-TNFα agents were shown to produce the highest degree of severity of sides’ effects, but 
these events remains extremely rare. But the presence of a cardiopulmonary arrest after 
infliximab (Remicade®) therapy, in the absence of history of allergy justify their use as third 
line therapeutic agent. Humanized antibodies may be an excellent alternative, but their use is 
limited to third line therapy in most countries. 
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       Table 1 Demographics and diagnosis            
                                              
        
Number of patients  23 
      
Sex     
Boys   12 (52%) 
Girls   11 (48%) 
      
Age at first consultation (year) 8.1 (1.7 - 15.6) 
      
Localization of uveitis    
Anterior   12 (52%) 
Intermediate   8 (35%) 
Panuveitis   2 (9%) 
Posterior   1 (4%) 
    
Laterality of uveitis    
Unilateral   4 (17%) 
Bilateral   19 (83%) 
      
Associated disease    
Intermediate uveitis  8 (35%) 
Juvenile idiopathic arthritis  7 (30%) 
Behçet's disease  3 (13%) 
HLA-B27   1 (4%) 
Vogt-Koyanagi-Harada   1 (4%) 
Idiopathic   3 (13%) 
  
Number of patients treated 
by     
Prednisone  22 (96%)  
Methotrexate   13 (57%) 
Azathioprine   7 (30%) 
Ciclosporine   1 (4%) 
Anti-TNFα   8 (35%) 
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         Table 2 Moderate and severe adverse events appearing with the systemic therapies 
 
 
 
 
 
 
 
 
Therapies Adverse events Number/total  Mean time of Patient/year index 
    (moderate and severe) patients onset (months)     
          
Prednisone Nausea/vomiting 
Weight gain and/or Cushing facies 
Ocular affects (ocular hypertension or 
cataract or glaucoma) 
Lymphopenia 
Arterial hypertension 
Delay in the growth and weight under 
percentile three 
14/22 (64%) 0.1 
8.1 (SD : 6.8) 
7.2 (SD : 5.0) 
 
5.5 (SD : 4.6) 
7.9 
10.9 
26.6 
             
Methotrexate Hepatotoxicity (ASAT/ALAT) 7/13 (54%) 15.6 (SD : 8.8) 22.1 
   Lymphopenia        
             
Azathioprine Hepatotoxicity (ASAT/ALAT) 1/7 (14%) 6.3 15.2 
             
Anti-TNFα 1) Limping, pain and erythema 2/8 (25%) 0 14 
   (Adalimumab  (Humira®))        
   2) Stage III anaphylactic shock   12.2    
    (Infliximab (Remicade®))             
 12 
 
                  Figure 1  Description of the different steps of treatment for the 23 children with quality of inflammation's control 
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